Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study.

  title={Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study.},
  author={Zs{\'o}fia N{\'e}meth and Anna Szűcs and J{\'o}zsef Vitrai and D{\'o}ra Juh{\'a}sz and J{\'a}nos P{\'a}l N{\'e}meth and Andr{\'a}s Holl{\'o}},
  journal={Ideggyogyaszati szemle},
  volume={74 11-12},
Background and purpose We aimed to investigate the association between fluoxetine use and the survival of hospitalised coronavirus disease (COVID-19) pneumonia patients. Methods This retrospective case-control study used data extracted from the medical records of adult patients hospitalised with moderate or severe COVID-19 pneumonia at the Uzsoki Teaching Hospital of the Semmelweis University in Budapest, Hungary between 17 March and 22 April 2021. As a part of standard medical treatment… 

Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness

A large designed study of 500 individuals hospitalized with COVID-19 in a large academic hospital system who were taking a serotonergic antidepressant at the time of admission and two groups not receiving an antidepressant found no significant difference in effect between the antidepressant group and either of the two comparison groups.

COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review

The best evidence of an “anti–COVID-19” potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine, according to a scoping review including clinical studies on AD effects on SARS-CoV-2 infection and CO VID-19.

The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis

Most of the evidence supports that the use of antidepressant medications, mainly Fluvoxamine may decrease the severity and improve the outcome in hospitalizes patients with sars-cov-2.

Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19

  • N. HoertelM. Sánchez-Rico On Behalf Of Ap-Hp/Université Paris Cité/Inserm Co
  • Medicine, Psychology
    Journal of clinical medicine
  • 2022
Antidepressants with high FIASMA (Functional Inhibitors of Acid Sphingomyelinase) activity seem to drive both associations of SARS-CoV-2 infections and COVID-19-related mortality in inpatients, and may be appropriate for prophylaxis and/or CO VID-19 therapy for outpatients or inpat patients.

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

The aim of the current study was to investigate the impact of SSRI/SNRIs on outcomes of COVID‐19 patients.

Antidepressants for COVID-19: A systematic review

Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day

Overall, with a minimum treatment period of 10-days and a minimum dose of 20 mg/day, this study corroborates in vitro studies reporting fluoxetine inhibiting SARS-CoV-2 titers and also multiple observational clinical studies showing therapeutic benefit of fluoxettine in COVID-19 patients.

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19

An overview of previous knowledge on the tissue distribution of fluoxetine and fluvoxamine is provided and by integrating this information with the published experimental results, the real opportunity of using these drugs in the fight against COVID-19 is highlighted.

Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model

The antiviral and anti-inflammatory properties of fluoxetine are demonstrated in a K18-hACE2 mouse model of SARS-CoV-2 infection, and its in vitro antiviral activity against variants of concern are established, establishing fluxetine as a very promising candidate for the prevention and treatment of Sars- CoV- 2 infection and disease pathogenesis.

Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France